公开(公告)号：US20170119902A1

公开(公告)日：2017-05-04

申请号：US15341834

申请日：2016-11-02

Applicant: Industrial Technology Research Institute

Inventor： Yi-Ju KO ,  Jheng-Sian LI ,  Maggie LU ,  On LEE ,  Ping-Fu CHENG ,  Chun-Min LIU

IPC: A61K47/48

CPC classification number: C07K7/02 ,  A61K47/551 ,  A61K47/6817 ,  A61K47/6889 ,  C07K5/0207

Abstract: An antibody-drug conjugate (ADC) of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), p is an integer ranging from 1 to 26, A is an antibody, and -(L-D) is a linker-drug unit. L is a linker unit having a glycopeptide, and D is a drug unit. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. A method for forming an antibody-drug conjugate (ADC) is also provided. A-(L-D)p  (I)

公开(公告)号：US20240016954A1

公开(公告)日：2024-01-18

申请号：US18471821

申请日：2023-09-21

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Wen-Chia HUANG ,  Yen-Jen WANG ,  Felice CHENG ,  Chia-Ching CHEN ,  Shao-Chan YIN ,  Chien Lin PAN ,  Tsan-Lin HU ,  Meng-Nan LIN ,  Kuo-Kuei HUANG ,  Maggie LU ,  Chih-Peng LIU

IPC: A61K47/69 ,  A61K47/22 ,  A61K9/00 ,  A61K9/08 ,  A61K47/10 ,  A61K47/32 ,  A61K47/40 ,  A61K47/38

CPC classification number: A61K47/6951 ,  A61K47/22 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/0053 ,  A61K9/08 ,  A61K47/10 ,  A61K47/32 ,  A61K47/40 ,  A61K47/38 ,  A61K31/47

Abstract: A composition for improving the solubility of poorly soluble substances is provided. The composition for improving the solubility of poorly soluble substances includes 60-97% by weight of cyclodextrin and/or a derivative thereof, 0.5-4% by weight of at least one water-soluble polymer and 0.4-30% by weight of at least one water-soluble stabilizer, wherein the at least one water-soluble stabilizer includes caffeine, and wherein the poorly soluble substance is a tyrosine kinase inhibitor.

公开(公告)号：US20180110731A1

公开(公告)日：2018-04-26

申请号：US15788920

申请日：2017-10-20

Applicant: Industrial Technology Research Institute

Inventor： Wen-Hsuan CHIANG ,  Yu-Wen LO ,  Felice CHENG ,  Maggie LU ,  Ya-Ling CHIU

IPC: A61K9/06 ,  A61K47/10 ,  A61K47/34 ,  C07K16/32 ,  A61K33/30 ,  A61K39/395 ,  A61K38/26 ,  A61K38/38 ,  A61K38/17 ,  A61K31/704

CPC classification number: A61K9/06 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/704 ,  A61K33/30 ,  A61K38/1793 ,  A61K38/26 ,  A61K38/385 ,  A61K39/39541 ,  A61K39/39558 ,  A61K47/10 ,  A61K47/34 ,  A61K47/42 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/94

Abstract: A hydrogel composition is provided. The hydrogel composition includes polyglutamic acid (PGA) containing maleimide groups, and polyethylene glycol (PEG) containing terminal thiol groups, wherein the hydrogel composition has a pH value ranging from 4.0 to 6.5. A drug delivery system is also provided. The drug delivery system includes the above-mentioned hydrogel composition, and a pharmaceutically active ingredient encapsulated in the hydrogel composition.

公开(公告)号：US20190209706A1

公开(公告)日：2019-07-11

申请号：US16232601

申请日：2018-12-26

Applicant: Industrial Technology Research Institute

Inventor： Wen-Chia HUANG ,  Yen-Jen WANG ,  Felice CHENG ,  Chia-Ching CHEN ,  Shao-Chan YIN ,  Chien-Lin PAN ,  Tsan-Lin HU ,  Meng-Nan LIN ,  Kuo-Kuei HUANG ,  Maggie LU ,  Chih-Peng LIU

IPC: A61K47/69 ,  A61K31/569 ,  A61K47/38 ,  A61K9/08

CPC classification number: A61K47/6951 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/4439 ,  A61K31/569 ,  A61K47/38 ,  A61K47/40 ,  A61K47/65

Abstract: A composition for improving the solubility of poorly soluble substances is provided. The composition includes about 40-99.5% by weight of cyclodextrin and/or derivatives thereof; about 0.05-10% by weight of at least one water-soluble polymer; and about 0.05-60% by weight of at least one water-soluble stabilizer.

公开(公告)号：US20160361268A1

公开(公告)日：2016-12-15

申请号：US15142170

申请日：2016-04-29

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Chih-Peng LIU ,  Ya-Chin LO ,  Ming-Cheng WEI ,  Maggie LU ,  Shuen-Hsiang CHOU ,  Shih-Ta CHEN ,  Hsiang-Wen TSENG

IPC: A61K9/51 ,  A61K33/24 ,  A61K9/00 ,  A61K31/282

CPC classification number: A61K9/5161 ,  A61K9/0019 ,  A61K31/555 ,  A61K33/24

Abstract: Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C4-C20 alkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C4-C20 alkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.

Abstract translation: 公开了使用透明质酸纳米颗粒治疗淋巴癌的淋巴内递送方法。 这些纳米颗粒包括透明质酸衍生物和铂化合物。 透明质酸衍生物包括透明质酸，修饰的组氨酸和任选的一种或多种聚合物或C 4 -C 20烷基。 透明质酸衍生物可以包括连接聚合物或C4-C20烷基与透明质酸的连接基团。 铂化合物包括二氯（1,2-二氨基环己烷）铂（DACHPt），顺铂和奥沙利铂。 这种淋巴内递送方法在使用铂药物治疗淋巴癌方面具有显着的优势。